Related Experiment Video
Updated: Jun 21, 2026
09:18
Correlative Light Electron Microscopy (CLEM) for Tracking and Imaging Viral Protein Associated Structures in Cryo-immobilized Cells
Published on: September 7, 2018
How HCV has changed the approach to mixed cryoglobulinemia
A Della Rossa1, C Baldini, A Tavoni
1Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy.
Clinical and Experimental Rheumatology
|August 4, 2009
Summary
Mixed cryoglobulinemia, a vasculitis linked to viral infections like Hepatitis C virus (HCV), shows promise with new B-lymphocyte therapies. Combined antiviral and cytotoxic treatments may offer better outcomes for this complex disease.
Area of Science:
- Immunology
- Rheumatology
- Hepatology
- Virology
Background:
- Mixed cryoglobulinemia is an immune-complex mediated vasculitis with a known viral origin, particularly Hepatitis C virus (HCV).
- Traditional treatments focused on viral eradication, but antiviral therapies have shown limited efficacy and potential side effects.
- Immunosuppressive therapies were historically discouraged due to concerns about promoting viral replication and contraindications with certain biological agents.
Purpose of the Study:
- To evaluate the potential of novel targeted therapies, specifically B-lymphocyte-directed treatments like rituximab, for mixed cryoglobulinemia.
- To reconsider the therapeutic approach for HCV-related mixed cryoglobulinemia in light of emerging treatment options and safety profiles.
- To explore the potential benefits of combined antiviral and cytotoxic therapies for managing severe complications of the disease.
Main Methods:
- Review of preliminary results from trials using B-lymphocyte-targeted therapies (e.g., rituximab).
- Analysis of safety profiles from small open trials of biological agents in HCV-positive arthritis patients.
- Examination of historical data on chemotherapy use in the pre-HCV discovery era and during HCV-related lymphoma.
Main Results:
- Preliminary results for B-lymphocyte-targeted therapies in mixed cryoglobulinemia are promising.
- Biological agents have demonstrated an acceptable safety profile in HCV-positive arthritis patients.
- Past chemotherapy regimens, even aggressive ones, showed low rates of severe liver damage in HCV-related conditions.
Conclusions:
- The therapeutic strategy for HCV-related mixed cryoglobulinemia warrants reconsideration.
- Targeted therapies against B-lymphocytes and combined antiviral and cytotoxic approaches show potential.
- Future research should focus on multi-step treatment strategies combining novel antiviral and cytotoxic agents.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:27Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:15Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...